Aug 15
Opportunity
Access to clinical trials may be limited depending upon the participant’s circumstance. Providing support services (e.g., transportation assistance) may help to eliminate logistical barriers to participation.
Considerations to Help Action the Opportunity
- Incorporate input from participants, care partners and sites to proactively develop a plan to implement support services
- Partner with investigative sites to understand if support service(s) is suitable for the clinical setting and their participants
- Define reimbursement options, including how and what to reimburse, tailoring services to the sites’ and patients’ needs, such as:
- Accessibility supports
- Transportation assistance
- Accommodation assistance
- Care of dependents
- Food
- Out-of-pocket
- Consider how to provide reimbursement in a timely manner
- Identify a single point-of-contact for participant coordination on all relevant support services, including navigating insurance where applicable
- Consider extending hours of operation for participants to attend in evenings or weekends
- Understand the timing of assessments to help minimize participant burden, such as reducing the need to fast all day and facilitating out-of-hours collections or windows for collection (e.g., lab samples testing over the weekend or an allowance that these can be stored over the weekend to facilitate collection of samples on a Friday)
Value and Potential Benefits
- Allows greater access to clinical trials and helps further support patients to remain enrolled
- Maximizes flexibility in the type of study visits available for participant with less logistic burden
- Increases convenience to participate regardless of participant’s life circumstances (e.g., barriers to trial participation due to health status, financial background, logistical burdens, mental blockades, and insecurities)
Related Blog Posts
Why the biggest gains in clinical R&D won’t come from technology
Every few years, the clinical research industry rallies around a new wave of innovation. From decentralised trials and digital biomarkers to AI driven automation, each wave brings genuine capability andpromise. Read the full article featuring Kelsey Jakee on page 38 here.
Enough, already: the problem with clinical trial data collection
The clinical research ecosystem has never been more technologically capable — or more burdened by its own ambition. In December 2025, the Tufts Center for the Study of Drug Development and our team at TransCelerate published research that suggests nearly 30% of the data collected in clinical trials do not directly inform key decisions, yet patients are…
2026 DIA Global Annual Meeting: What the FDA’s Real-Time Data Push Actually Means for Sponsors and CROs
In this video interview from the 2026 DIA Global Annual Meeting, Kevin Bugin, head of global regulatory policy and intelligence at Amgen and executive sponsor of TransCelerate’s Embedded Pragmatic Trials initiative, reframes the FDA’s continuous review expectations around real-time evidence generation and explains why quality by design—not data cleanup—is what regulators are now demanding. Watch…
